Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05091047 · ClinicalTrials.gov registry record · NA
Effect of the Erchonia® EVRL OTC™ for the Relief of Diabetic Peripheral Neuropathy Foot Pain
A NA study, sponsored by Erchonia Corporation.
- Completed
- Registry status
- NA
- Development phase
- 9
- Enrollment target
NCT05091047: Completed NA study, sponsored by Erchonia Corporation.
NCT05091047 is a NA study that has completed, run by Erchonia Corporation. The registered enrollment target is 9 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05091047, a NA study, has completed, sponsored by Erchonia Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 9 participants
- Enrollment target
Study Summary
This study is to see if applying red and violet low-level laser light can help to reduce foot pain associated with diabetic peripheral neuropathy,
Primary Outcome
The Numerical Rating Scale (NRS) assesses the level or degree of pain. With '0: no pain at all' and '100: worst pain imaginable. The subject will be asked to rate the level of foot pain he or she is experiencing at that time.
Interventions
- DEVICE Erchonia EVRL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2021-06-16 |
| Est. Completion | 2021-12-01 |
| Phase | NA |
What the finished NCT05091047 record still lists
NCT05091047 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Erchonia EVRL is the first listed.
NCT05091047 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05091047 about?
NCT05091047 is a clinical study titled "Effect of the Erchonia® EVRL OTC™ for the Relief of Diabetic Peripheral Neuropathy Foot Pain". This study is to see if applying red and violet low-level laser light can help to reduce foot pain associated with diabetic peripheral neuropathy,
What is the current status of trial NCT05091047?
This trial is currently completed. It is a NA study. The enrollment target is 9 participants. The study started on 2021-06-16. Estimated completion is 2021-12-01.
What interventions are being tested in trial NCT05091047?
The interventions under investigation include: Erchonia EVRL (DEVICE).
Who is sponsoring clinical trial NCT05091047?
This trial is sponsored by Erchonia Corporation, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05091047's enrollment target sits among peer trials
9 1975th of 2000 higher than 25 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI